Huntsman Cancer Institute at the University of Utah | Strategic Alliance Partners

April 08, 2019

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses unmet needs in metastatic renal cell carcinoma (mRCC).

March 13, 2019

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the combination of lenvatinib (Lenvima) and everolimus in the treatment of patients with metastatic renal cell carcinoma (mRCC).

February 23, 2019

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses findings from the KEYNOTE-426 study in patients with metastatic renal cell carcinoma.

January 31, 2019

Neeraj Agarwal, MD, discusses his preferred sequencing strategies in the treatment of patients with mRCC.

January 04, 2019

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses second-line therapy selection in metastatic renal cell carcinoma.

September 05, 2018

Benjamin L. Maughan, MD, PharmD, discusses the tolerability of combining radium-223 dichloride and enzalutamide, as well as the next steps with this combination.

August 14, 2018

Brock O’Neil, MD, assistant professor, Division of Urology, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the current standard of care in muscle-invasive bladder cancer.

July 20, 2018

Brock O’Neil, MD, assistant professor, Division of Urology, University of Utah School of Medicine, Huntsman Cancer Institute, discusses emerging therapeutic techniques in bladder cancer.

July 18, 2018

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses his preferred frontline treatment for patients with kidney cancer.

January 12, 2018

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the advantages and disadvantages of choosing docetaxel as a therapy for patients with mCRPC.

November 27, 2017

Neeraj Agarwal, MD, recaps the latest advancements in newly diagnosed RCC.

November 14, 2017

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses remaining questions in renal cell carcinoma.

February 24, 2017

A new study has provided yet more evidence that survivors of endometrial cancer should be closely monitored for cardiovascular disease.

November 25, 2015

Robert Andtbacka, MD, discusses how the role of oncolytic immunotherapies continues to evolve in melanoma and gives a better understanding of what is on the horizon for the novel therapeutics.

September 14, 2015

Due to the unique characteristics of adolescents and young adults, there is a growing effort to address their oncology needs.

May 06, 2015

Although CLL is the most common chronic leukemia, there remains no single agreed-upon standard of care for first-line treatment.

January 23, 2015

Jonathan Tward, MD, PhD, Associate Professor of Radiation Oncology at the Huntsman Cancer Institute, discusses abbreviated course androgen-deprivation therapy (ADT) for prostate cancer treatment.

October 17, 2014

Does renal disease increase one's risk of developing cancer?

September 08, 2014

Robert H. I. Andtbacka, MD, CM, from Intermountain Healthcare and Huntsman Cancer Institute, discusses the safety and efficacy of T-VEC in combination with ipilimumab in patients with previously untreated, unresected stage IIIB-IV melanoma.

July 03, 2014

There are few controversies in oncology as divisive as the value of prostate-specific antigen (PSA) screening and subsequent treatment for prostate cancer.